Study: Double-blind, placebo-controlled, phase 3 study Untreated unresectable or metastatic biliary tract cancer Gemcitabine – cisplatin plus Durvalumab (341) or placebo (344) Efficacy: 24 month OS: 24.9% vs. 10.4% ORR:
Study: Open-label phase 1–2 trial Previously platinum-based chemotherapy Advanced or metastatic RET fusion positive NSCLC pts who had been treated with platinum (phase I: 49 pts) and who were untreated
Study: Double-blind, randomized Phase III trial (COSMIC-311) RAI-refractory differentiated thyroid cancer pts with prior lenvatinib or sorafenib Cabozantinib 60 mg daily vs. placebo Efficacy: ORR: 18% vs. 0% Median PFS:
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.